Skip to main content
. 2021 Oct 8;2(10):e213177. doi: 10.1001/jamahealthforum.2021.3177

Table 2. Spending and Use of Drugs With Accelerated Approval Relative to All Drugsa.

Year Drugs with accelerated approval All drugs Spending on drugs with accelerated approval, % Prescriptions of drugs with accelerated approval, %
Gross spending, $ Net spending, $ Prescriptions Gross spending, $ Net spending, $ Prescriptions
2015 4 156 129 280 2 205 562 624 2 418 753 62 803 562 496 34 604 761 088 696 103 872 6.4 0.4
2016 4 652 082 176 2 482 836 224 2 285 451 69 404 336 128 33 869 318 144 744 184 320 7.3 0.3
2017 4 861 428 736 2 601 984 512 1 998 629 71 650 836 480 32 601 131 008 764 512 704 8.0 0.3
2018 4 696 761 344 2 508 952 320 1 550 386 68 267 962 368 27 648 522 240 740 410 496 9.1 0.2
2019 4 691 189 760 2 592 940 288 1 304 768 68 526 755 840 30 357 352 448 699 248 064 8.5 0.2
a

Gross spending represents the total amount reported in the State Medicaid Drug Utilization Data files reimbursed by Medicaid for the drugs in question, inclusive of both federal and state shares. Net spending reduces this total to account for Medicaid rebates paid back by manufacturers under the program. These figures are expected to be higher than the actually reimbursed amounts, which are based on average manufacturer price data that are not publicly available.